Cargando…
Icosapent ethyl: scientific and legal controversies
Icosapent ethyl (Vascepa) is a purified preparation of the omega-3 fatty acid eicosapentaenoic acid, which is marketed by Amarin Pharma based in Ireland. The product was initially approved by the US Food and Drug Administration for the use of a high dose (4 g/day) in the treatment of hypertriglyceri...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8070860/ https://www.ncbi.nlm.nih.gov/pubmed/33888593 http://dx.doi.org/10.1136/openhrt-2021-001616 |
_version_ | 1783683568215523328 |
---|---|
author | Curfman, Gregory Shehada, Emile |
author_facet | Curfman, Gregory Shehada, Emile |
author_sort | Curfman, Gregory |
collection | PubMed |
description | Icosapent ethyl (Vascepa) is a purified preparation of the omega-3 fatty acid eicosapentaenoic acid, which is marketed by Amarin Pharma based in Ireland. The product was initially approved by the US Food and Drug Administration for the use of a high dose (4 g/day) in the treatment of hypertriglyceridaemia. On the basis of the results of the REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl Intervention Trial), the agency later granted a label extension to include the additional indication of a reduction in risk of cardiovascular events in persons with serum triglyceride levels of 150 mg/dL or greater and established cardiovascular disease or diabetes. Data supporting the efficacy of omega-3 fatty acids in the prevention of cardiovascular disease have been inconsistent and controversial. The story of the development of icosapent ethyl has been fraught with challenges, including the invalidation of six core patents on the product, and recently, the completion of a new clinical trial, STRENGTH (Long-Term Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia), that directly contradicts REDUCE-IT and calls into question whether icosapent ethyl is actually effective in the secondary prevention of cardiovascular events. This article traces the course of the development of this fascinating product and discusses its complex medical, regulatory and legal history, which is still continuing to unfold. |
format | Online Article Text |
id | pubmed-8070860 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-80708602021-05-11 Icosapent ethyl: scientific and legal controversies Curfman, Gregory Shehada, Emile Open Heart Viewpoint Icosapent ethyl (Vascepa) is a purified preparation of the omega-3 fatty acid eicosapentaenoic acid, which is marketed by Amarin Pharma based in Ireland. The product was initially approved by the US Food and Drug Administration for the use of a high dose (4 g/day) in the treatment of hypertriglyceridaemia. On the basis of the results of the REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl Intervention Trial), the agency later granted a label extension to include the additional indication of a reduction in risk of cardiovascular events in persons with serum triglyceride levels of 150 mg/dL or greater and established cardiovascular disease or diabetes. Data supporting the efficacy of omega-3 fatty acids in the prevention of cardiovascular disease have been inconsistent and controversial. The story of the development of icosapent ethyl has been fraught with challenges, including the invalidation of six core patents on the product, and recently, the completion of a new clinical trial, STRENGTH (Long-Term Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia), that directly contradicts REDUCE-IT and calls into question whether icosapent ethyl is actually effective in the secondary prevention of cardiovascular events. This article traces the course of the development of this fascinating product and discusses its complex medical, regulatory and legal history, which is still continuing to unfold. BMJ Publishing Group 2021-04-22 /pmc/articles/PMC8070860/ /pubmed/33888593 http://dx.doi.org/10.1136/openhrt-2021-001616 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Viewpoint Curfman, Gregory Shehada, Emile Icosapent ethyl: scientific and legal controversies |
title | Icosapent ethyl: scientific and legal controversies |
title_full | Icosapent ethyl: scientific and legal controversies |
title_fullStr | Icosapent ethyl: scientific and legal controversies |
title_full_unstemmed | Icosapent ethyl: scientific and legal controversies |
title_short | Icosapent ethyl: scientific and legal controversies |
title_sort | icosapent ethyl: scientific and legal controversies |
topic | Viewpoint |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8070860/ https://www.ncbi.nlm.nih.gov/pubmed/33888593 http://dx.doi.org/10.1136/openhrt-2021-001616 |
work_keys_str_mv | AT curfmangregory icosapentethylscientificandlegalcontroversies AT shehadaemile icosapentethylscientificandlegalcontroversies |